407 related articles for article (PubMed ID: 19224764)
21. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
van den Bent MJ; Carpentier AF; Brandes AA; Sanson M; Taphoorn MJ; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Haaxma-Reiche H; Kros JM; van Kouwenhoven MC; Vecht CJ; Allgeier A; Lacombe D; Gorlia T
J Clin Oncol; 2006 Jun; 24(18):2715-22. PubMed ID: 16782911
[TBL] [Abstract][Full Text] [Related]
22. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
23. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
Smith JS; Perry A; Borell TJ; Lee HK; O'Fallon J; Hosek SM; Kimmel D; Yates A; Burger PC; Scheithauer BW; Jenkins RB
J Clin Oncol; 2000 Feb; 18(3):636-45. PubMed ID: 10653879
[TBL] [Abstract][Full Text] [Related]
24. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.
Jiang H; Ren X; Cui X; Wang J; Jia W; Zhou Z; Lin S
Neuro Oncol; 2013 Jun; 15(6):775-82. PubMed ID: 23486687
[TBL] [Abstract][Full Text] [Related]
25. How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic.
van den Bent MJ
Am Soc Clin Oncol Educ Book; 2013; ():114-6. PubMed ID: 23714473
[TBL] [Abstract][Full Text] [Related]
26. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
[TBL] [Abstract][Full Text] [Related]
27. Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines.
Michaud K; de Tayrac M; D'Astous M; Duval C; Paquet C; Samassekou O; Gould PV; Saikali S
PLoS One; 2016; 11(12):e0168728. PubMed ID: 28030632
[TBL] [Abstract][Full Text] [Related]
28. Prognosis of oligodendroglial tumor with ring enhancement showing central necrotic portion.
Choi KY; Jung TY; Jung S; Kim YH; Moon KS; Kim IY; Kang SS; Lee KH
J Neurooncol; 2011 May; 103(1):103-10. PubMed ID: 20737192
[TBL] [Abstract][Full Text] [Related]
29. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Brandes AA; Tosoni A; Cavallo G; Reni M; Franceschi E; Bonaldi L; Bertorelle R; Gardiman M; Ghimenton C; Iuzzolino P; Pession A; Blatt V; Ermani M;
J Clin Oncol; 2006 Oct; 24(29):4746-53. PubMed ID: 16954518
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of chromosome 1p/19q deletion by Fluorescence in Situ Hybridization (FISH) as prognostic factors in malignant glioma patients on treatment with alkylating chemotherapy.
Pandith AA; Zahoor W; Manzoor U; Nisar S; Guru FR; Naikoo NA; Aein QU; Baba SM; Bhat AR; Ganai F; Shah P
Cancer Genet; 2023 Nov; 278-279():55-61. PubMed ID: 37625215
[TBL] [Abstract][Full Text] [Related]
31. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
Andrews C; Prayson RA
Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
[TBL] [Abstract][Full Text] [Related]
32. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
Speirs CK; Simpson JR; Robinson CG; DeWees TA; Tran DD; Linette G; Chicoine MR; Dacey RG; Rich KM; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):268-76. PubMed ID: 25636755
[TBL] [Abstract][Full Text] [Related]
33. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
Erdem-Eraslan L; Gravendeel LA; de Rooi J; Eilers PH; Idbaih A; Spliet WG; den Dunnen WF; Teepen JL; Wesseling P; Sillevis Smitt PA; Kros JM; Gorlia T; van den Bent MJ; French PJ
J Clin Oncol; 2013 Jan; 31(3):328-36. PubMed ID: 23269986
[TBL] [Abstract][Full Text] [Related]
34. Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors.
Chen H; Thomas C; Munoz FA; Alexandrescu S; Horbinski CM; Olar A; McGuone D; Camelo-Piragua S; Wang L; Pentsova E; Phillips J; Aldape K; Chen W; Iafrate AJ; Chi AS; Zagzag D; Golfinos JG; Placantonakis DG; Rosenblum M; Ohman-Strickland P; Hameed M; Snuderl M
Neuro Oncol; 2019 Sep; 21(9):1164-1174. PubMed ID: 31140557
[TBL] [Abstract][Full Text] [Related]
35. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.
Snuderl M; Eichler AF; Ligon KL; Vu QU; Silver M; Betensky RA; Ligon AH; Wen PY; Louis DN; Iafrate AJ
Clin Cancer Res; 2009 Oct; 15(20):6430-7. PubMed ID: 19808867
[TBL] [Abstract][Full Text] [Related]
36. Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours.
Kim JW; Park CK; Park SH; Kim YH; Han JH; Kim CY; Sohn CH; Chang KH; Jung HW
J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):224-7. PubMed ID: 20587495
[TBL] [Abstract][Full Text] [Related]
37. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival.
Felsberg J; Erkwoh A; Sabel MC; Kirsch L; Fimmers R; Blaschke B; Schlegel U; Schramm J; Wiestler OD; Reifenberger G
Brain Pathol; 2004 Apr; 14(2):121-30. PubMed ID: 15193024
[TBL] [Abstract][Full Text] [Related]
38. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
; Cairncross G; Berkey B; Shaw E; Jenkins R; Scheithauer B; Brachman D; Buckner J; Fink K; Souhami L; Laperierre N; Mehta M; Curran W
J Clin Oncol; 2006 Jun; 24(18):2707-14. PubMed ID: 16782910
[TBL] [Abstract][Full Text] [Related]
39. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP
Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770
[TBL] [Abstract][Full Text] [Related]
40. Anaplastic oligodendroglial tumors harboring 1p/19q deletion can be successfully treated without radiotherapy.
Iwadate Y; Matsutani T; Shinozaki N; Saeki N
Anticancer Res; 2011 Dec; 31(12):4475-9. PubMed ID: 22199318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]